Home › Opioid Overdose › NCT07128524
Ketones for Opioid Craving
Ketone Supplementation for Opioid Craving and Withdrawal
Who can join
Ages 18 to 75 · All sexes
Full eligibility criteria
Inclusion Criteria: * Age 18-75 years * Meets currents DSM-5 criteria for OUD and admitted for opioid withdrawal management treatment at Caron Treatment Center * Willingness to provide signed, informed consent and commit to completing the procedures in the study Exclusion Criteria: * Current severe gastrointestinal (GI), liver, or other clinically significant physical disease that may interfere with the intake of the ketone supplement (e.g., sever inflammatory bowel disease, cirrhosis). * Currently taking (within the past two weeks) GLP-1 receptor agonist medications, e.g. semaglutide, which can interfere with the absorption of the ketone supplement * Currently pregnant or lactating, for people of childbearing potential * Judged by the principal investigator. study physician, or their designee to be an unsuitable candidate for the study
About the study
The goal of this clinical trial is to learn if ketone supplementation (KS) works to reduce craving for opioids for adults with opioid use disorder (OUD) undergoing in-patient acute withdrawal management. The main questions it aims to answer are:
* Does KS reduce craving for opioids in patients with opioid use disorder? * Does KS reduce symptoms of opioid withdrawal such as low mood and pain? Researchers will compare KS to a placebo to see if KS works to reduce craving for opioids and reduce withdrawal symptoms in adults entering in-patient acute withdrawal management for opioid use disorder.
Participants will:
* Be given KS or a placebo three (3) times daily for seven (7) days * Complete mood, pain tolerance, and subjective opioid withdrawal assessments
What is being tested
- Treatment with Ketone Supplement (dietary supplement)
- Treatment with Placebo (dietary supplement)
Sponsor: University of Maryland, Baltimore · Participants: 50 · Started: Jul 16, 2026
Contact the study team
- Peter Manza, PhD · Phone: 410-706-2814
- Kynah Walston, MA · Phone: 443-974-7951
Official record on ClinicalTrials.gov — NCT07128524
Locations in the U.S.
| Pennsylvania | Caron Pennsylvania Addiction Treatment and Rehab Center, Wernersville |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.